Cargando…
Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
Antibodies against PD1 have been used to treat progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by JC virus. We used these antibodies (nivolumab) to treat PML in 3 kidney transplant recipients. All died within 8 weeks of diagnosis. Hence, nivolumab did not improve PML ou...
Autores principales: | Medrano, Chloé, Vergez, François, Mengelle, Catherine, Faguer, Stanislas, Kamar, Nassim, Del Bello, Arnaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810212/ https://www.ncbi.nlm.nih.gov/pubmed/31625858 http://dx.doi.org/10.3201/eid2511.190705 |
Ejemplares similares
-
Possible patient to patient transmission of progressive multifocal leukoencephalopathy among kidney-transplant patients
por: Lajaunie, Rebecca, et al.
Publicado: (2020) -
Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021) -
Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors
por: Boumaza, Xavier, et al.
Publicado: (2022) -
Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study
por: Faguer, Stanislas, et al.
Publicado: (2022) -
An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients
por: Pambrun, Emilie, et al.
Publicado: (2014)